Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion.
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Humans
Glycated Hemoglobin
/ metabolism
Diabetes Mellitus, Type 2
/ drug therapy
Canagliflozin
/ therapeutic use
Glucosides
/ therapeutic use
Benzhydryl Compounds
/ therapeutic use
Glycosuria
Dose-Response Relationship, Drug
Thiophenes
/ therapeutic use
Randomized Controlled Trials as Topic
Glucose
/ metabolism
Diabetes
Model-based meta-analysis
Pharmacometrics
SGLT2 inhibitor
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
27
06
2024
accepted:
11
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
This study was aimed to evaluate whether the dose-response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)-canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin-can be explained in a unified manner based on their ability to promote urinary glucose excretion (UGE). Information on HbA1c reduction at various doses of each SGLT2i was collected from literatures on randomized controlled trials and was normalized based on the daily UGE data from phase I studies. After normalizing doses, the dose-response relationship of HbA1c reduction of most of SGLT2is was represented by a unified nonlinear mixed-effect model, with the estimated maximum HbA1c (%) reduction (E
Identifiants
pubmed: 39433865
doi: 10.1038/s41598-024-76256-6
pii: 10.1038/s41598-024-76256-6
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Glycated Hemoglobin
0
Canagliflozin
0SAC974Z85
Glucosides
0
dapagliflozin
1ULL0QJ8UC
Benzhydryl Compounds
0
empagliflozin
HDC1R2M35U
hemoglobin A1c protein, human
0
ipragliflozin
3N2N8OOR7X
Thiophenes
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
24695Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21K06797
Organisme : Japan Society for the Promotion of Science
ID : 21K06797
Informations de copyright
© 2024. The Author(s).
Références
Seltzer, H. S., Allen, E. W., Herron, A. L. Jr. & Brennan, M. T. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest. 46, 323–335. https://doi.org/10.1172/jci105534 (1967).
doi: 10.1172/jci105534
pubmed: 6023769
pmcid: 297053
Tabák, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215–2221. https://doi.org/10.1016/s0140-6736(09)60619-x (2009).
doi: 10.1016/s0140-6736(09)60619-x
pubmed: 19515410
pmcid: 2726723
Jabbour, S. A. & Goldstein, B. J. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279–1284. https://doi.org/10.1111/j.1742-1241.2008.01829.x (2008).
doi: 10.1111/j.1742-1241.2008.01829.x
pubmed: 18705823
Yakovleva, T. et al. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes. Metab. 21, 2684–2693. https://doi.org/10.1111/dom.13858 (2019).
doi: 10.1111/dom.13858
pubmed: 31423699
He, X. et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of sotagliflozin after multiple ascending doses in chinese healthy subjects. Drug Des. Devel. Ther. 16, 2967–2980. https://doi.org/10.2147/dddt.S372575 (2022).
doi: 10.2147/dddt.S372575
pubmed: 36097559
pmcid: 9464004
Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7, e30555. https://doi.org/10.1371/journal.pone.0030555 (2012).
doi: 10.1371/journal.pone.0030555
pubmed: 22355316
pmcid: 3280264
Tahara, A. et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 385, 423–436. https://doi.org/10.1007/s00210-011-0713-z (2012).
doi: 10.1007/s00210-011-0713-z
pubmed: 22139434
Kurosaki, E. & Ogasawara, H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 139, 51–59. https://doi.org/10.1016/j.pharmthera.2013.04.003 (2013).
doi: 10.1016/j.pharmthera.2013.04.003
pubmed: 23563279
Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723–1729. https://doi.org/10.2337/db07-1472 (2008).
doi: 10.2337/db07-1472
pubmed: 18356408
Grempler, R. et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14, 83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x (2012).
doi: 10.1111/j.1463-1326.2011.01517.x
pubmed: 21985634
Ohtake, Y. et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 55, 7828–7840. https://doi.org/10.1021/jm300884k (2012).
doi: 10.1021/jm300884k
pubmed: 22889351
Kakinuma, H. et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J. Med. Chem. 53, 3247–3261. https://doi.org/10.1021/jm901893x (2010).
doi: 10.1021/jm901893x
pubmed: 20302302
Palmer, S. C. et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis. Jama 316, 313–324. https://doi.org/10.1001/jama.2016.9400 (2016).
doi: 10.1001/jama.2016.9400
pubmed: 27434443
Teo, Y. N. et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: A network meta-analysis of 111 randomized controlled trials. Am. J. Cardiovasc. Drugs 22, 299–323. https://doi.org/10.1007/s40256-022-00528-7 (2022).
doi: 10.1007/s40256-022-00528-7
pubmed: 35316484
Shi, F. H. et al. High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 23, 2125–2136. https://doi.org/10.1111/dom.14452 (2021).
doi: 10.1111/dom.14452
pubmed: 34048142
Phung, O. J., Scholle, J. M., Talwar, M. & Coleman, C. I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Jama 303, 1410–1418. https://doi.org/10.1001/jama.2010.405 (2010).
doi: 10.1001/jama.2010.405
pubmed: 20388897
Shyangdan, D. S., Uthman, O. A. & Waugh, N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6, e009417. https://doi.org/10.1136/bmjopen-2015-009417 (2016).
doi: 10.1136/bmjopen-2015-009417
pubmed: 26911584
pmcid: 4769433
Maloney, A., Rosenstock, J. & Fonseca, V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin. Pharmacol. Ther. 105, 1213–1223. https://doi.org/10.1002/cpt.1307 (2019).
doi: 10.1002/cpt.1307
pubmed: 30457671
Kowa Company LSKK. Deberza Tablets 20mg/Apleway Tablets 20mg (Tofogliflozin hydrate) CTD. (2014).
Astellas Pharma I. Suglat Tablets 25 mg/50 mg, CTD (Ipragliflozin L-Proline). CTD 2.7.2. (2014).
Bristol-Myers KK. Forxiga 5 mg/10 mg tablets CTD (Dapagliflozin propandiol monohydrate). CTD 2.7.2. (2014).
Yao, X. et al. A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors. CPT Pharmacom. Syst. Pharmacol. 12, 487–499. https://doi.org/10.1002/psp4.12934 (2023).
doi: 10.1002/psp4.12934
Polidori, D. et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36, 2154–2161. https://doi.org/10.2337/dc12-2391 (2013).
doi: 10.2337/dc12-2391
pubmed: 23412078
pmcid: 3714520
Wright, E. M., Hirayama, B. A. & Loo, D. F. Active sugar transport in health and disease. J. Intern. Med. 261, 32–43. https://doi.org/10.1111/j.1365-2796.2006.01746.x (2007).
doi: 10.1111/j.1365-2796.2006.01746.x
pubmed: 17222166
DeFronzo, R. A., Davidson, J. A. & Del Prato, S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 14, 5–14. https://doi.org/10.1111/j.1463-1326.2011.01511.x (2012).
doi: 10.1111/j.1463-1326.2011.01511.x
pubmed: 21955459
Ohgaki, R. et al. Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J. Pharmacol. Exp. Ther. 358, 94–102. https://doi.org/10.1124/jpet.116.232025 (2016).
doi: 10.1124/jpet.116.232025
pubmed: 27189972
Suga, T. et al. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol. Metab. 19, 1–12. https://doi.org/10.1016/j.molmet.2018.10.009 (2019).
doi: 10.1016/j.molmet.2018.10.009
pubmed: 30416006
DeFronzo, R. A., Stonehouse, A. H., Han, J. & Wintle, M. E. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet. Med. 27, 309–317. https://doi.org/10.1111/j.1464-5491.2010.02941.x (2010).
doi: 10.1111/j.1464-5491.2010.02941.x
pubmed: 20536494
Inoue, H. et al. Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis. Br. J. Clin. Pharmacol. 85, 393–402. https://doi.org/10.1111/bcp.13807 (2019).
doi: 10.1111/bcp.13807
pubmed: 30394576
Sarashina, A. et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin. Ther. 36, 1606–1615. https://doi.org/10.1016/j.clinthera.2014.08.001 (2014).
doi: 10.1016/j.clinthera.2014.08.001
pubmed: 25199997
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306. https://doi.org/10.1056/NEJMoa1811744 (2019).
doi: 10.1056/NEJMoa1811744
pubmed: 30990260
Chertow, G. M. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol. 32, 2352–2361. https://doi.org/10.1681/asn.2021020167 (2021).
doi: 10.1681/asn.2021020167
pubmed: 34272327
pmcid: 8729835
Kluger, A. Y. et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc. Diabetol. 18, 99. https://doi.org/10.1186/s12933-019-0903-4 (2019).
doi: 10.1186/s12933-019-0903-4
pubmed: 31382965
pmcid: 6683461
Brath, H., Paldánius, P. M., Bader, G. & Mathieu, C. Relationship between duration of type 2 diabetes and effectiveness of DPP-4 inhibitor versus sulfonylurea as add-on therapy: A post hoc analysis. Diabetes Ther. 8, 829–836. https://doi.org/10.1007/s13300-017-0276-1 (2017).
doi: 10.1007/s13300-017-0276-1
pubmed: 28631242
pmcid: 5544613
Iemitsu, K. et al. Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin: Interim analysis of the ASSIGN-K study. J. Clin. Med. Res. 8, 373–378. https://doi.org/10.14740/jocmr2492w (2016).
doi: 10.14740/jocmr2492w
pubmed: 27081422
pmcid: 4817576
Di Franco, A. et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int. J. Cardiol. 243, 86–90. https://doi.org/10.1016/j.ijcard.2017.05.032 (2017).
doi: 10.1016/j.ijcard.2017.05.032
pubmed: 28526540
Lee, S. Y. et al. Sodium/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction. Korean Circ. J. 51, 251–262. https://doi.org/10.4070/kcj.2020.0303 (2021).
doi: 10.4070/kcj.2020.0303
pubmed: 33655725
Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71. https://doi.org/10.1136/bmj.n71 (2021).
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Mitsubishi Tanabe Pharma Corporation. CANAGLU 100 mg tablets (Canagliflozin Hydrate) CTD. CTD 2.7.2. (2014).
Nippon Boehringer Ingelheim CL. Jardiance 10 mg/25 mg tablets CTD (Empagliflozin). CTD 2.7.2. (2014).
TAISHO PHARMACEUTICAL HOLDINGS CO. L. Lusefi 2.5 mg/5 mg tablets CTD (Luseogliflozin Hydrate). CTD 2.7.2. (2014).